Mar 04, 2024 / 04:10PM GMT
Stephen Michael Scala - TD Cowen, Research Division - MD & Senior Research Analyst
Well, good morning once again. We're delighted to have Pfizer here at Cowen's 44th Annual Healthcare Conference. Representing the company, Dave Denton, who is Chief Financial Officer as well as Executive Vice President, will start out. Dave is going to give a few thoughts about Pfizer and the outlook, and then we'll dive into our questions as well, as very importantly, your questions.
David M. Denton - Pfizer Inc. - CFO & Executive VP
Great. Thank you. And thank you again for hosting me, Steve, and my Investor Relations team, and thank you for your interest in Pfizer. Before I get started, my lawyers want me to make sure that I disclose that today we might make some forward-looking statements and discussion of many non-GAAP measures. You can see some explanation of that and some additional information in our SEC filings and on our Investor Relations website at Pfizer.
So with that, again, thank you again for your interest in Pfizer. I just want to make sure --
Pfizer Inc at TD Cowen Health Care Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot